From target to KRAS broad range treatment - FLORE
Osimertinib, predicted by our computational platform during the course of this study, acts upstream of KRAS. G12C to inhibit EGFR, specifically ...
Targeting KRAS mutations in pancreatic cancer - Semantic ScholarOur findings support TEAD inhibition as a therapeutic combination strategy to enhance the response rate and durability of direct KRAS inhibitor therapies. Conquering oncogenic KRAS and its bypass mechanismsOne strategy to overcome resistance and to provide better disease control could be combination strategies to address the escape mechanisms in ... KRAS: Biology, Inhibition, and Mechanisms of Inhibitor ResistanceThese findings demonstrate the benefit of combining BI-3406 with a KRASG12Ci to treat KRASG12C- mutated tumors that have acquired resistance to ...
Autres Cours:
